Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Waters (WAT) Q2 Earnings Beat On Broad-Based Sales Growth

Published 07/24/2017, 10:04 PM
Updated 07/09/2023, 06:31 AM

Waters Corporation (NYSE:WAT) has a brilliant earnings beat streak, spanning 11 quarters of positive earnings surprises, which the company broke with in-line earnings in one of the quarters last year. In second-quarter 2017, Waters Corp. continued its impressive streak, as the company’s adjusted earnings of $1.76 per share trumped the Zacks Consensus Estimate of $1.72 by 2.3%.

The bottom-line figure fared even better in year-over-year comparison, reflecting striking growth of 11.4% from the prior-year quarter tally of $1.58. Remarkable broad-based top-line expansion, along with spectacular growth in Asia, aided the earnings beat.

Solid operational execution backed by the company’s efficient business model also lent strength to the results. Further, a decline in interest expenses aided quarterly profits.

Inside the Headlines

In the reported quarter, Waters Corp.’s net sales grew 4% year over year to $558 million and also came ahead of the Zacks Consensus Estimate of $552.9 million.

The upside in the top line came on the back of robust performance in the industrial end markets (up 7% on a constant currency basis) and the bio/pharmaceutical end market (up 4% on a constant currency basis). The momentum was further aided by growth of 5% (on a constant currency basis) in the government and academic markets.

Also, impressive contribution from sale of key products across major geographies supplemented quarterly sales growth. In addition, Water Corp.’s recurring revenues and instrument system sales grew 5% and 3%, respectively, driving top-line growth.

In terms of geographies, Waters Corp. witnessed strong sales in Asia and Europe, which posted 14% and 5% growth, respectively, at constant currency. However, sales in the Americas continued to reflect weakness and declined 3% year over year.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Total selling and administrative expenses in the quarter came in at $130.2 million, up from $129.6 million incurred in second-quarter 2016. Research and development outlay for the quarter was $32.9 million compared with $32.6 million incurred a year ago.

Despite the rise in these expenses, operating income in the quarter climbed 1.4% year over year to $118.9 million.

Waters Corporation Price, Consensus and EPS Surprise

Liquidity

Waters Corp.’s cash, cash equivalents and investments at the quarter end amounted to just over $3 billion, higher than the $2.81 billion recorded as on Dec 31, 2016. The company’s total liabilities at quarter end increased to about $2.48 billion from $2.36 billion as on Dec 31, 2016.

Our Take

Waters Corp.’s leading position in the high-performance liquid chromatography and mass spectrometry markets is its key strength that has acted as a strong revenue driver for the past few quarters. The company’s bright pharmaceutical business started 2017 on a healthy note and looks set to continue its momentum, going ahead. It is also seeing encouraging trends in its industrial businesses. The governmental and academic markets have also turned its performance around and look poised to maintain the growth trend, in the coming quarters.

Waters Corp.’s exposure in the pharma/biotech industry is primarily in regulated commercial lab environments, where demand is non-discretionary and not prone to cyclicality. This helps the company mitigate uncertain client spending stemming from macroeconomic volatility. Additionally, given the fact that liquid chromatography is used in a huge variety of applications, Waters Corp. is well poised to benefit significantly from this business, moving ahead.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Zacks Rank & Other Stocks to Consider

Waters Corp. currently holds a Zacks Rank #2 (Buy).

Some other similarly-ranked stocks in the same space include Bruker Corporation (NASDAQ:BRKR) , Mettler-Toledo International, Inc. (NYSE:MTD) and PerkinElmer, Inc. (NYSE:PKI) . You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Bruker Corporation generated two huge beats in the trailing four quarters, for an average positive surprise of 21.1%.

Mettler-Toledo has a striking earnings surprise history for the last four quarters, having beaten estimates all through, for an average beat of 5.3%.

PerkinElmer also has a decent earnings surprise history, with an average beat of 0.73% for the trailing four quarters, beating estimates thrice.

More Stock News: Tech Opportunity worth $386 Billion in 2017

From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.

Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>



Waters Corporation (WAT): Free Stock Analysis Report

PerkinElmer, Inc. (PKI): Free Stock Analysis Report

Bruker Corporation (BRKR): Free Stock Analysis Report

Mettler-Toledo International, Inc. (MTD): Free Stock Analysis Report
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.